Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits.
Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa. A rabbit model of bacterial keratitis was used to assess the in vivo efficacy of topical ciprofloxacin. Albino rabbits received intrastromal injections of 5 X 10(2) aminoglycoside-resistant P aeruginosa organisms. At five hours after inoculation, ciprofloxacin (3 mg/mL) therapy was initiated (one drop every 30 minutes for 12 hours). Corneal tissue was then excised for bacterial colony counts. No organisms were recovered from ciprofloxacin-treated eyes, compared with an average of 3.1 X 10(7) organisms per milliliter recovered from untreated controls. This model suggests that topical ciprofloxacin may be clinically useful in the treatment of aminoglycoside-resistant P aeruginosa keratitis.
D000287:Administration, Topical; D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003315:Cornea / Q000378:metabolism; D007634:Keratitis / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D011817:Rabbits
D009883:Ophthalmic Solutions; D002939:Ciprofloxacin